Hyperfractionated Cyclophosphamide As Urgent Therapy: A Single Institution Experience.

e19045 Background: Hematologic cancers can present with severe issues such as airway compromise, hypercalcemia, etc. Due to high drug costs and payment concerns, therapies that are inexpensive but effective are necessary. Within our institution, we utilize hyperfractionated cyclophosphamide (cyclophosphamide 300 mg/m 2 IV q 12 hours X 6) [HyperC] for these patients. We opted to see if this approach is justified. Methods: We reviewed data via our EMR of people who received HyperC. Data was limited to urgent therapy. Data was collected from 2015-2017. The cost of therapy was also looked at relative to other therapies with our pharmacy team. Categories are as per the charts below. Results: See Table. Conclusions: HyperC is cost effective and efficacious for patients who need urgent therapy. [Table: see text][Table: see text][Table: see text]